Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hosing, C.
Right arrow Articles by Khouri, I. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hosing, C.
Right arrow Articles by Khouri, I. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:737-744, 2003
© 2003 European Society for Medical Oncology

Original Paper

Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin’s lymphoma

C. Hosing, R. M. Saliba, P. McLaughlin, B. Andersson, M. A. Rodriguez, L. Fayad, F. Cabanillas, R. E. Champlin and I. F. Khouri+

Departments of Blood and Marrow Transplantation and Lymphoma, University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA

Received 4 October 2002; revised 9 January 2003; accepted 21 January 2003

Background:

The aim of this study was to compare the outcomes of high-dose therapy (HDT) and allogeneic versus autologous hematopoietic stem cell transplantation (SCT) in patients with refractory or recurrent indolent non-Hodgkin’s lymphoma (NHL).

Patients and methods:

From January 1991 to March 2000, 112 patients underwent HDT followed by either autologous (68 patients) or allogeneic (44 patients) SCT for refractory or recurrent indolent NHL. Prior conventional chemotherapy had failed in all patients.

Results:

The two groups were similar with respect to age at transplantation, gender, histological subtypes, number of chemotherapy regimens received before transplantation and International Prognostic Index scores. The median time from diagnosis to transplantation was longer in the autologous than in the allogeneic SCT group (46 versus 27 months, P = 0.002). In the allogeneic SCT group the median follow-up time was 53 months (range 21–113), and the overall survival (OS) and disease-free survival (DFS) rates were 49% and 45%, respectively. After a median follow-up time of 71 months (range 22–109), in the autologous SCT group, the OS and DFS rates were 34% and 17%, respectively. Patients who underwent autologous SCT were more likely to have chemosensitive disease (P <0.001) and were more likely to be in complete remission at the time of transplantation (P = 0.001) than those who underwent allogeneic SCT. However, the probability of disease progression was significantly higher in the autologous SCT group than in the allogeneic SCT group (74% versus 19%, P = 0.003).

Conclusions:

Patients who undergo HDT with allogeneic SCT for refractory or recurrent indolent NHL have lower relapse rates but higher treatment-related mortality rates than patients who undergo autologous SCT. However, with the development of non-myeloablative preparative regimens, which can decrease treatment-related mortality, patients with recurrent indolent NHL should be considered for controlled trials of allogeneic transplantation if they have a human leukocyte antigen-identical donor.

Key words: allogeneic stem cell transplantation, autologous stem cell transplantation, indolent non-Hodgkin’s lymphoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
A. J. Moskowitz and C. H. Moskowitz
Controversies in the Treatment of Lymphoma with Autologous Transplantation
Oncologist, September 1, 2009; 14(9): 921 - 929.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. F. Khouri
Response: Choice of conditioning for allogeneic transplantation in follicular lymphoma: nonmyeloablative or high-dose chemotherapy?
Blood, September 15, 2008; 112(6): 2586 - 2587.
[Full Text] [PDF]

Home page
 haematolHome page
N. Schmitz, P. Dreger, B. Glass, and A. Sureda
Allogeneic transplantation in lymphoma: current status
Haematologica, November 1, 2007; 92(11): 1533 - 1548.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
L. Farina and P. Corradini
Current role of allogeneic stem cell transplantation in follicular lymphoma
Haematologica, May 1, 2007; 92(5): 580 - 582.
[Full Text] [PDF]

Home page
 haematolHome page
S. Vigouroux, M. Michallet, R. Porcher, M. Attal, L. Ades, M. Bernard, D. Blaise, R. Tabrizi, F. Garban, J.-P. Cassuto, et al.
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)
Haematologica, May 1, 2007; 92(5): 627 - 634.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
D. G. Maloney
Follicular NHL: From Antibodies and Vaccines to Graft-versus-Lymphoma Effects
Hematology, January 1, 2007; 2007(1): 226 - 232.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. F. Khouri, M.-S. Lee, R. M. Saliba, G. Jun, L. Fayad, A. Younes, B. Pro, S. Acholonu, P. McLaughlin, R. L. Katz, et al.
Nonablative Allogeneic Stem-Cell Transplantation for Advanced/Recurrent Mantle-Cell Lymphoma
J. Clin. Oncol., December 1, 2003; 21(23): 4407 - 4412.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.